TickerFacts.

Gilead Sciences, Inc. (GILD): Free Cash Flow

Operating cash flow minus capital expenditures for the same annual period and currency, computed by TickerFacts from the filed figures. A simple proxy, not a reported figure; a year without both inputs is left out.

$9.46B
Year ended 2025-12-31
$12.94B
Trailing 12 months to 2026-06-30
+4.3%
3-year compound annual growth
+4.7%
5-year compound annual growth
$10.80B2013-12-31: $2.97B2018-12-31: $7.48B2019-12-31: $8.32B2020-12-31: $7.52B2021-12-31: $10.80B2022-12-31: $8.34B2023-12-31: $7.42B2024-12-31: $10.30B2025-12-31: $9.46B$9.46B
2013-12-31 Free Cash Flow (USD) 2025-12-31
Period endedFree Cash FlowChange YoYSource filing
2025-12-31$9.46B-8.2%2026-02-24, From 2025-01-01
2024-12-31$10.30B+38.9%2026-02-24, From 2024-01-01
2023-12-31$7.42B-11.1%2026-02-24, From 2023-01-01
2022-12-31$8.34B-22.8%2025-02-28, From 2022-01-01
2021-12-31$10.80B+43.7%2024-02-23, From 2021-01-01
2020-12-31$7.52B-9.6%2023-02-22, From 2020-01-01
2019-12-31$8.32B+11.3%2022-02-23, From 2019-01-01
2018-12-31$7.48Bn/a2021-02-25, From 2018-01-01
No annual figure between 2013-12-31 and 2018-12-31.
2013-12-31$2.97Bn/a2016-02-24, From 2013-01-01

Free Cash Flow at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedFree Cash FlowChange YoY
Gilead Sciences, Inc. (GILD)2025-12-31$9.46B-8.2%
Amgen Inc (AMGN)2025-12-31$8.10B-22.1%
Biogen Inc. (BIIB)2025-12-31$2.05B-24.7%
Neurocrine Biosciences Inc (NBIX)2025-12-31$748.70M+34.4%
Exelixis, Inc. (EXEL)2026-01-02$875.84M+30.4%
Qiagen N.V. (QGEN)2025-12-31$453.28M-10.5%
Moderna, Inc. (MRNA)2025-12-31-$2.06Bn/m
Halozyme Therapeutics, Inc. (HALO)2025-12-31$644.59M+37.6%
Bio-Techne Corp (TECH)2026-06-30$263.22M+2.6%

Compare GILD, AMGN, BIIB, NBIX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗